Personal and Home Care Products
CIRS Group
Chemicals
Cosmetic
Food
Medical Devices
Agrochemicals
CIRS Testing
Carbon Neutrality
Search
China
On January 6, 2026, according to the National Medical Products Administration (NMPA), a new cosmetic ingredient has completed the filing process. This marks the first new cosmetic ingredient filing approved in 2026.
On January 4, 2025, China's National Medical Products Administration (NMPA) announced the third dynamic adjustment to theInventory of Existing Cosmetic Ingredients in China (IECIC).
Following FAQs are all related to ordinary cosmetics filing, CIRS Group has compiled the information and translated them into English for your reference.
In accordance with Article 78 of the Cosmetics Supervision and Administration Regulations, products that had obtained administrative licenses for five categories of former special purpose cosmetics—namely hair growth, hair removal, breast enhancement, body slimming, and deodorant—prior to January 1, 2021, under the former Regulations on Hygiene Supervision of Cosmetics, were granted a unified transition period ending on December 31, 2025.
This article compiles and summarizes the latest developments in cosmetics regulations in China and globally as of November 2025, covering industry news, newly issued regulations, latest standards updates, relevant policy adjustments, and regulatory requirements. It aims to assist enterprises in ensuring compliance and keeping up with global cosmetics regulatory trends.
Per- and polyfluoroalkyl substances (PFAS) are increasingly becoming a focal point of global concern due to their potential long-term impacts on the environment and human health. As a class of synthetic chemicals characterized by high stability and widespread applications, PFAS are facing increasingly stringent regulatory scrutiny in the cosmetics sector. This article explores the physicochemical properties and potential health risks of PFAS, and systematically reviews the evolving global regulatory landscape related to their use in cosmetics. It aims to help cosmetic enterprises gain a comprehensive understanding of regulatory requirements, mitigate compliance risks, enhance product safety, and strengthen competitiveness in international markets.
This article provides a consolidated overview of the relevant regulatory notices, supplemented by recent developments in regulatory enforcement activities-such as unannounced inspections and sampling inspections-conducted by the National Medical Products Administration (NMPA) and selected provincial and municipal authorities. The aim is to assist enterprises in staying informed of evolving regulatory trends and to reinforce awareness of quality management and compliance requirements.
Based on data retrieved from China’s National Medical Products Administration (NMPA), three new cosmetic ingredients have successfully been filed between December 1 and December 3, 2025. Detailed information is provided in the table below. At present, the associated technical specifications have not been made public, and the ingredient has not yet entered the post-filing monitoring period. As of now, a total of 152 new cosmetic ingredients have been successfully filed in 2025.
To help stakeholders stay informed of the latest developments and gain insights into market trends, this article provides a systematic review and in-depth analysis of the cosmetic ingredient filings published by China’s National Medical Products Administration (NMPA) in November 2025. The report mainly covers the number of new ingredient filings during the month, basic information about the filing enterprises, the regional distribution of domestic filers, ingredients that have been filed multiple times, and interpretations of selected ingredients. It aims to offer valuable data support and information references for the cosmetics industry.
To help stakeholders stay informed of the latest developments and gain insights into market trends, this article provides a systematic review and in-depth analysis of the cosmetic ingredient filings published by China’s National Medical Products Administration (NMPA) in October 2025. The report mainly covers the number of new ingredient filings during the month, basic information about the filing enterprises, the regional distribution of domestic filers, ingredients that have been filed multiple times, and interpretations of selected ingredients. It aims to offer valuable data support and information references for the cosmetics industry.
国产一区二区不卡